Rationally-selected microbiota (RSM™) Therapies are defined groups of human-derived microbes, carefully selected for their ability to interact with other microbes and the host to drive clinical results.
At Finch, our mission to harness the therapeutic potential of the microbiome to transform human health, pushes us to look beyond natural microbial therapies to develop Rationally-Selected Microbiota therapies.
rationally-selected microbiota therapies are distinct from existing microbial therapies
Rationally-Selected Microbiota therapies represent a new generation of microbial therapy, unlike either traditional probiotics or natural microbial therapies.
Rationally-Selected Microbiota therapies build on the well-characterized nature of probiotics and the physiological relevance of natural microbial therapies to create defined compositions of human-adapted, therapeutic microbes. By enabling the rational design of synthetic ecologies, we are opening the door to a new class of microbial therapy.
FIN-524, a microbial cocktail for ulcerative colitis, is our first product candidate based on this philosophy.